Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 9, Issue 1, Pages 13-26Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2015.1092381
Keywords
autoimmune disease; cholangitis; obeticholic acid; primary biliary cirrhosis; ursodeoxycholic acid
Categories
Funding
- UK Medical Research Council
- NIHR Biomedical Research Unit
- Wellcome Trust
- MRC [MR/L001489/1] Funding Source: UKRI
- Medical Research Council [MR/L001489/1] Funding Source: researchfish
Ask authors/readers for more resources
Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve biochemical response, signifying a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic regeneration in preclinical studies. Data from recent Phase II and III controlled trials suggest a therapeutic impact of OCA in PBC biochemical nonresponders, as evidenced by change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a common adverse effect, but may be overcome through dose-titration. Longer term studies are needed with focus on safety and long-term clinical efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available